Cagrilintide is a long-acting amylin analog that works through a different satiety circuit, with monotherapy data showing close to 10.8 percent loss over roughly six months
Limitations 1 : 1 : Results should be interpreted with caution because of the retrospective pre-post design without a control or comparator arm and the relatively short follow-up (6 months) Hypoglycemia may have been underreported, as only the clinically significant events were likely to have been captured (eg, no SMBG or CGM data) EMR database analysis as a potential for selection bias that cannot be controlled, as well as EMR data-capture challenges (eg, coding errors, no dosing data) Patients were mainly from the Northwest and Southern US states and therefore may not be representative of the US national landscape Sanofi-sponsored study *Follow-up period 6 months included GLP-1 RA + Toujeo (N=271)
Constipation treatment approaches are similar across the class
Movement also improves communication between the digestive system and the brain, helping satiety signals work more effectively
Cell Stem Cell 8 , 281293 (2011)
Certain conditions make these peptides inappropriate, which is exactly why a supervised evaluation comes first
